医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

‘China (Zhangjiajie) Giant Salamander’ Public Exhibition (Longyan Station) Has Concluded Successfully

2014年10月01日 PM04:00
このエントリーをはてなブックマークに追加


 

ZHANGJIAJIE, China

The public exhibition (Longyan Station) of the ‘China (Zhangjiajie) Giant Salamander’ was held in Sunrise City Mall, Longyan, Fujian Province, China from 19 September to 21 September 2014. It was co-organized by SHINIQUE of Jinchi Biotech Ltd. and Chaoyanhuitian Health & Beauty Chain.

The joint sponsor of Jinchi Biotech Ltd for the exhibition, Chaoyanhuitian Health & Beauty Chain, is a most influential regular chain enterprise of cosmetic industry in Longyan, Fujian Province. They own 7 health & beauty regular chain stores and a cosmetic occupation skill training school.

With ‘Live Green and Protect Giant Salamander’ as its theme, during the 3 days of exhibition, the exhibition had attracted over 1,000 visitors; and exhibited Zhangjiajie Giant Salamander, Zhangjiajie Giant Salamander Museum, SHINIQUE Skin Care Products, and SHINIQUE Health Care Products to the city of Longyan. The ‘China (Zhangjiajie) Giant Salamander’ Public Exhibition (Longyan Station) had awesome effects in that 90% of the invited customers had purchased Jinchi SHINIQUE products on the exhibition which means Jinchi Biotech Ltd. had made more than RMB 200,000 of sales on the exhibition. It was continued the amazing effects of the JBL ‘SHINIQUE Health Journey’.

ABOUT JINCHI

www.jc-biotech.com

Owning the world’s only Giant Salamander Museum, Jinchi Biotech Ltd. mainly specialized in the R&D of giant salamander related biotech products with more than 40 skincare and health products under two product lines, namely SHINIQUE and ANDRIAS. With strong scientific research background and a comprehensive business model, Jinchi Biotech Ltd. values virtue and goodwill, commits to deliver quality products to consumers, and devotes to the health, beauty and biomedical industries.

Disclaimer

The statements contained herein are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements.

CONTACT

Jinchi Biotech Ltd.
Chan Luo, +86-731-8979-2661
ir@jc-biotech.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Brightree发布面向居家医疗器械的首个患者App
  • Brightreeが初のHME向け患者アプリを発表
  • Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer
  • ポットネットワーク・ホールディングスがSEC報告会社登録に基づきPCAOB監査人による完全な監査・レビュー済みの財務報告書を公表
  • Takeda Receives Clearance from the Japan Fair Trade Commission for the Proposed Acquisition of Shire plc